COGT.US Cogent Biosciences Inc

Healthcare Biotechnology USA Stocks
28.56 USD
Close of Nov 14, 2026
27.74 43.73
Market cap
USD 4.97B
P/E
-
P/B
11.24x
ROE
-78.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is COGT.US undervalued?

Graham number

The Graham number of Cogent Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cogent Biosciences Inc fundamental analysis

No fundamental analysis for Cogent Biosciences Inc yet.

Cogent Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cogent Biosciences Inc

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced ga…

Full company profile